NCT02065336 - A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Hepatitis B, Chronic

Interventions

DRUG

ARC-520

DRUG

Placebo

DRUG

entecavir

DRUG

chlorpheniramine

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

Trial Locations (2)

Queen Mary Hospital, Pokfulam

Prince of Wales Hospital, Shatin